Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:50 PM
Ignite Modification Date:
2025-12-24 @ 2:50 PM
NCT ID:
NCT01011959
Eligibility Criteria:
Inclusion Criteria:
* Patients with an established diagnosis of Rheumatoid Arthritis
* Patients currently treated with concomitant methotrexate for at least 12 weeks, with a stable dose for at least 6 weeks
Exclusion Criteria:
* Persistent chronic or current active infections
* Patients who have taken anakinra within 2 weeks
* Patients who have taken etanercept, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 4 weeks
* Patients who have taken adalimumab within 6 weeks
* Patients who have taken abatacept, azathioprine, cyclophosphamide or infliximab within 12 weeks
* Patients who have taken leflunomide or rituximab within 6 months
* Patients who have had prior treatment with tocilizumab or any other anti-IL-6 medication
* Significant arthritis or other medical condition that could interfere with study evaluations
* Participation in any clinical research study evaluating another investigational drug within 30 days
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01011959
Study Brief:
Protocol Section:
NCT01011959